KRAS and non-small cell lung carcinoma: We observed a number of previously unreported resistance mechanisms to EGFR TKIs in NSCLC patients, including a novel tertiary mutation in EGFR (L798I) and the emergence of activating KRAS mutations in patients following rociletinib therapy.